Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Jonathan Roberts

Pediatrics Peoria, IL Medical Doctor

NPI 1871757070 CMS profile 1014764

427 W Northmoor Rd, Peoria, IL 61614

Open in the dashboard

General payments

$587,656

410 records reported · program years 2019–2025

Research payments

$4,030

Paid to them · 4 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$1,076,849 paid to institutions, not to them · program years 2019–2025

Through program year 2025, Jonathan Roberts of Peoria, IL is reported in the CMS Open Payments database as having received $587,656 across 410 general payments and $4,030 in research payments paid to them. Separately, studies naming them as principal investigator received $1,076,849 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 99th percentile of Pediatrics profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

9 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $107,287 43
2024 General $106,542 64
2023 General $111,533 68
2022 General $109,737 78
2021 General $41,557 38
2021 Research $3,730 3
2020 General $55,111 35
2020 Research $300 1
2019 General $55,889 84

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jonathan Roberts
  • Pediatrics median
  • Middle half of Pediatrics
  • National median

In program year 2025, general payments to Jonathan Roberts were reported at $107,287. Among 22,296 Pediatrics profiles paid that year, the median was $97 and the middle half received between $37 and $210.

Show as a table
Year Jonathan Roberts Pediatrics median Middle half National median
2019 $55,889 $86 $31–$183 $163
2020 $55,111 $49 $22–$110 $114
2021 $41,557 $68 $27–$158 $132
2022 $109,737 $77 $30–$173 $149
2023 $111,533 $88 $33–$190 $160
2024 $106,542 $94 $34–$206 $164
2025 $107,287 $97 $37–$210 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Genzyme Corporation $157,723 96 payments
  2. Novo Nordisk Inc $137,554 85 payments
  3. Takeda Pharmaceuticals U.S.A., Inc. $108,600 82 payments
  4. Bioverativ Therapeutics Inc. $31,623 27 payments
  5. Genentech USA, Inc. $27,955 23 payments
  6. Shire North American Group Inc $27,047 40 payments
  7. Swedish Orphan Biovitrum AB $18,727 4 payments
  8. BioMarin Pharmaceutical Inc. $15,927 6 payments
  9. Pfizer Inc. $15,313 13 payments
  10. Sanofi US Services Inc. $14,912 1 payment
  11. Other $32,275 33 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $342,714 125 payments
  2. Consulting Fee $184,615 52 payments
  3. Travel and Lodging $40,942 103 payments
  4. Honoraria $11,250 6 payments
  5. Food and Beverage $7,904 115 payments
  6. Education $231 9 payments
Products named General payments · program years 2019–2025
  1. ALTUVIIIO Hematology $72,398 38 payments
  2. ADVATE $34,976 30 payments
  3. VONVENDI $31,136 25 payments
  4. HEMLIBRA $30,087 23 payments
  5. QFITLIA $29,982 17 payments
  6. ALPROLIX Hematology $19,424 20 payments
  7. ALTUVIIIO Hematology $18,727 4 payments
  8. Roctavian $15,927 6 payments
  9. NovoSeven $15,569 10 payments
  10. ALPROLIX Hematology $14,287 9 payments
  11. Other $72,036 71 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Takeda Pharmaceuticals U.S.A., Inc. $3,100 1 payment
  2. F. Hoffmann-La Roche AG $930 3 payments

Prescribing to Medicare patients

Part D · data year 2024 · 4 drugs

Part D claims

380

Median for Pediatric Medicine: 38

Drug cost

$167,337

Median for Pediatric Medicine: $2,769

Branded share of claims

48.2%

Median for Pediatric Medicine: 18.4%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 140 $119,704
Xarelto Rivaroxaban Brand 43 $42,257
Enoxaparin Sodium Generic 13 $3,262
Warfarin Sodium Generic 184 $2,114

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 3,361 Part D prescribers listed as Pediatric Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 19 billing codes

Paid by Medicare

$56,126

Medicare's payments for the services billed

Medicare patients

229

Average age 72

Services billed

864

116 women, 113 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 49%
Chronic kidney disease 41%
Diabetes 35%
Ischemic heart disease 34%
Heart failure 29%
Atrial fibrillation 27%
Depression 25%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

5 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
ALTUVIIIO
  • GENZYME CORPORATION $29,016
$29,016 — —
VONVENDI
  • Takeda Pharmaceuticals U.S.A., Inc. $9,149
$9,149 — —
ALPROLIX
  • GENZYME CORPORATION $7,579
$7,579 — —
ADVATE
  • Takeda Pharmaceuticals U.S.A., Inc. $5,621
$5,621 — —
ENJAYMO
  • GENZYME CORPORATION $35
$35 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

414 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Pediatrics in Illinois

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record